NYSEAMERICAN:NSPR - InspireMD Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.23 -0.01 (-4.17 %)
(As of 07/18/2018 03:05 AM ET)
Previous Close$0.23
Today's Range$0.22 - $0.23
52-Week Range$0.22 - $20.30
Volume485,000 shs
Average Volume783,436 shs
Market Capitalization$7.11 million
P/E RatioN/A
Dividend YieldN/A
Beta2.61
InspireMD logoInspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.

Receive NSPR News and Ratings via Email

Sign-up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:NSPR
CUSIPN/A
Phone+1-857-4536553

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-179.74%
Return on Equity-720.33%
Return on Assets-90.96%

Miscellaneous

EmployeesN/A
Outstanding Shares6,450,000
Market Cap$7.11

The Truth About Cryptocurrencies

InspireMD (NYSEAMERICAN:NSPR) Frequently Asked Questions

What is InspireMD's stock symbol?

InspireMD trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NSPR."

When did InspireMD's stock split? How did InspireMD's stock split work?

InspireMD shares reverse split on the morning of Thursday, February 8th 2018. The 1-35 reverse split was announced on Wednesday, February 7th 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 7th 2018. An investor that had 100 shares of InspireMD stock prior to the reverse split would have 3 shares after the split.

How were InspireMD's earnings last quarter?

InspireMD Inc (NYSEAMERICAN:NSPR) announced its quarterly earnings results on Monday, May, 7th. The medical equipment provider reported ($1.06) earnings per share (EPS) for the quarter. The medical equipment provider earned $1.01 million during the quarter. InspireMD had a negative net margin of 179.74% and a negative return on equity of 720.33%. View InspireMD's Earnings History.

What is the consensus analysts' recommendation for InspireMD?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InspireMD in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Are investors shorting InspireMD?

InspireMD saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 579,063 shares, an increase of 5.4% from the June 15th total of 549,631 shares. Based on an average daily volume of 1,629,206 shares, the days-to-cover ratio is currently 0.4 days. Currently, 11.3% of the shares of the stock are short sold. View InspireMD's Current Options Chain.

Who are some of InspireMD's key competitors?

Who are InspireMD's key executives?

InspireMD's management team includes the folowing people:
  • Dr. James J. Barry Ph.D., Pres, CEO & Director (Age 59)
  • Mr. Craig Shore, CFO, Chief Admin. Officer, Treasurer & Sec. (Age 57)
  • Mr. Agustin V. Gago, Exec. VP & Chief Commercial Officer (Age 58)
  • Dr. Sol J. Barer, Special Advisor to the Board (Age 71)
  • Mr. Benzi Spector, Head of R&D and Operations

Has InspireMD been receiving favorable news coverage?

Media coverage about NSPR stock has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. InspireMD earned a media sentiment score of 0.06 on Accern's scale. They also gave press coverage about the medical equipment provider an impact score of 45.47 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of InspireMD?

Shares of NSPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is InspireMD's stock price today?

One share of NSPR stock can currently be purchased for approximately $0.23.

How big of a company is InspireMD?

InspireMD has a market capitalization of $7.11 million.

How can I contact InspireMD?

InspireMD's mailing address is 4 Menorat Hamaor St., TEL AVIV-YAFO, MA 6744832, Israel. The medical equipment provider can be reached via phone at +1-857-4536553.


MarketBeat Community Rating for InspireMD (NYSEAMERICAN NSPR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  198
MarketBeat's community ratings are surveys of what our community members think about InspireMD and other stocks. Vote "Outperform" if you believe NSPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.